25 1086 4850
www.stocktitan.net
MIRA Reports Positive 7-Day Dog Study Results for SKNY-1
MIRA Pharmaceuticals (NASDAQ: MIRA) reported positive toxicokinetic results from a 7-day repeated-dose study of obesity candidate SKNY-1 in male and female Beagle dogs. Daily oral dosing showed rapid absorption, dose-dependent systemic exposure, and evidence of systemic accumulation, with similar plasma concentrations between sexes.According to MIRA, these findings de-risk dose selection and will guide design of planned GLP-compliant toxicology studies as part of the IND-enabling program. Prior peer-reviewed preclinical work with oral SKNY-1 showed dose-dependent weight loss with preserved lean body mass, lipid normalization, reduced hepatic triglycerides, and no anxiety-related effects despite CB1 pathway engagement.
